Stability Analysis of Smith predictor Based Networked Control Systems with Time-varying delays

S. Bonala,B. Subudhi,Sandip Ghosh

DOI: https://doi.org/10.2316/Journal.201.2014.3.201-2556

Control and Intelligent Systems

Abstract:

What problem does this paper attempt to address?

In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma

Qi Liu,Ye Tian,Yanyan Li,Wei Zhang,Wenxuan Cai,Yaju Liu,Yuefei Ren,Zhaoduan Liang,Peipei Zhou,Yajing Zhang,Yifeng Bao,Yi Li

DOI: https://doi.org/10.1136/jitc-2020-001748

IF: 12.469

2020-12-01

Journal for ImmunoTherapy of Cancer

Abstract:Background In patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), virus-specific cytotoxic T lymphocytes (CTLs) fail to eliminate HCC cells expressing HBV antigens. As the expression of viral antigen in HBV-associated HCC may decrease to allow tumor to escape immune attacks, we hypothesized that an HBV surface antigen (HBsAg)-specific affinity-improved-T-cell receptor (TCR) will enable T cells to target HCC more effectively than corresponding wild-type-TCR. We also postulated that TCR promiscuity can be exploited to efficiently capture HBV variants that can hinder CTL-based therapeutics. Methods We applied flexi-panning to isolate affinity-improved TCRs binding to a variant antigen, the human leukocyte antigen (HLA)-A*02:01-restricted nonapeptide HBs 371-379 -ILSPFLPLL, from libraries constructed with a TCR cloned using the decapeptide HBs 370-379 -SIVSPFIPLL. The potency and safety of the affinity-improved-TCR engineered T-cells (Ai-TCR-T) were verified with potentially cross-reactive human and HBV-variant peptides, tumor and normal cells, and xenograft mouse models. Results Ai-TCR-T cells retained cognate HBV antigen specificity and recognized a wide range of HBV genotypic variants with improved sensitivity and cytotoxicity. Cell infusions produced complete elimination of HCC without recurrence in the xenograft mouse models. Elevated accumulation of CD8 + Ai-TCR-T cells in tumors correlated with tumor shrinkage. Conclusion The in vitro and in vivo studies demonstrated that HBsAg-specific Ai-TCR-T cells had safety profiles similar to those of their wild-type counterparts and significantly enhanced potency. This study presents an approach to develop new therapeutic strategies for HBV-related HCC.

oncology,immunology
Targeted Delivery of Interferon-Α to Hepatitis B Virus-Infected Cells Using T-cell Receptor-Like Antibodies.

Changhua Ji,Konduru S. R. Sastry,Georg Tiefenthaler,Jennifer Cano,Tenny Tang,Zi Zong Ho,Denise Teoh,Sandhya Bohini,Antony Chen,Surya Sankuratri,Paul A. Macary,Patrick Kennedy,Han Ma,Stefan Ries,Klaus Klumpp,Erhard Kopetzki,Antonio Bertoletti

DOI: https://doi.org/10.1002/hep.25875

IF: 17.298

2012-01-01

Hepatology

Abstract:During antiviral therapy, specific delivery of interferon-alpha (IFN alpha) to infected cells may increase its antiviral efficacy, trigger a localized immune reaction, and reduce the side effects caused by systemic administration. Two T-cell receptor-like antibodies (TCR-L) able to selectively bind hepatitis B virus (HBV)-infected hepatocytes of chronic hepatitis B patients and recognize core (HBc18-27) and surface (HBs183-91) HBV epitopes associated with different human leukocyte antigen (HLA)-A*02 alleles (A*02:01, A*02:02, A*02:07, A*02:11) were generated. Each antibody was genetically linked to two IFN alpha molecules to produce TCR-L/IFN alpha fusion proteins. We demonstrate that the fusion proteins triggered an IFN alpha response preferentially on the hepatocytes presenting the correct HBV-peptide HLA-complex and that the mechanism of the targeted IFN alpha response was dependent on the specific binding of the fusion proteins to the HLA/HBV peptide complexes through the TCR-like variable regions of the antibodies. Conclusion: TCR-L antibodies can be used to target cytokines to HBV-infected hepatocytes in vitro. Fusion of IFN alpha to TCR-L decreased the intrinsic biological activity of IFN alpha but preserved the overall specificity of the protein for the cognate HBV peptide/HLA complexes. This induction of an effective IFN alpha response selectively in HBV-infected cells might have a therapeutic advantage in comparison to the currently used native or pegylated IFN alpha (HEPATOLOGY 2012;56:2027-2038)
A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy

Yue Wang,Yaxian Mei,Zhenghong Ao,Yuanzhi Chen,Yichao Jiang,Xiaoqing Chen,Ruoyao Qi,Baorong Fu,Jixian Tang,Mujin Fang,Min You,Tianying Zhang,Quan Yuan,Wenxin Luo,Ningshao Xia

DOI: https://doi.org/10.1016/j.antiviral.2022.105265

IF: 7.6

2022-03-01

Antiviral Research

Abstract:Sustainable viral suppression with hepatitis B surface antigen (HBsAg) loss is the new treatment goal for chronic hepatitis B (CHB). The role of antibodies in therapies for persistent hepatitis B virus (HBV) infection has received constant attention. While immunotherapy holds great promise, challenges for the antibody-based prevention and control of HBV in CHB include broad HBV antigenic diversity and the need for long-term viral suppression. In this study, we identified a new anti-HBsAg nanobody (Nb), 125s, isolated from HBsAg-immunized alpaca and confirmed its excellent potency in HBsAg clearance and broad-spectrum therapeutic activity against three HBV subtypes in vivo. In addition, we characterized a novel epitope at the C-terminus of the HBsAg surface motif from amino acids 157 to 174. A 125s-based long-term passive immunization program was efficacious at HBsAg clearance and inducing cellular immune responses, offering a promising outlook for CHB immunotherapy.

pharmacology & pharmacy,virology
A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations

Qiao Wang,Eleftherios Michailidis,Yingpu Yu,Zijun Wang,Arlene M Hurley,Deena A Oren,Christian T Mayer,Anna Gazumyan,Zhenmi Liu,Yunjiao Zhou,Till Schoofs,Kai-Hui Yao,Jan P Nieke,Jianbo Wu,Qingling Jiang,Chenhui Zou,Mohanmmad Kabbani,Corrine Quirk,Thiago Oliveira,Kalsang Chhosphel,Qianqian Zhang,William M Schneider,Cyprien Jahan,Tianlei Ying,Jill Horowitz,Marina Caskey,Mila Jankovic,Davide F Robbiani,Yumei Wen,Ype P de Jong,Charles M Rice,Michel C Nussenzweig,Arlene M. Hurley,Deena A. Oren,Christian T. Mayer,Kai-hui Yao,Jan P. Nieke,William M. Schneider,Davide F. Robbiani,Ype P. de Jong,Charles M. Rice,Michel C. Nussenzweig

DOI: https://doi.org/10.1016/j.chom.2020.05.010

2020-08-01

Abstract:Although there is no effective cure for chronic hepatitis B virus (HBV) infection, antibodies are protective and correlate with recovery from infection. To examine the human antibody response to HBV, we screened 124 vaccinated and 20 infected, spontaneously recovered individuals. The selected individuals produced shared clones of broadly neutralizing antibodies (bNAbs) that targeted 3 non-overlapping epitopes on the HBV S antigen (HBsAg). Single bNAbs protected humanized mice against infection but selected for resistance mutations in mice with prior established infection. In contrast, infection was controlled by a combination of bNAbs targeting non-overlapping epitopes with complementary sensitivity to mutations that commonly emerge during human infection. The co-crystal structure of one of the bNAbs with an HBsAg peptide epitope revealed a stabilized hairpin loop. This structure, which contains residues frequently mutated in clinical immune escape variants, provides a molecular explanation for why immunotherapy for HBV infection may require combinations of complementary bNAbs.

microbiology,virology,parasitology
HBsAg and TLR7/8 dual-targeting antibody-drug conjugates induce sustained anti-HBV activity in AAV/HBV mice: a preliminary study

Xinya Ye,Xiaoqing Chen,Han Liu,Yichao Jiang,Chengyu Yang,Tao Xu,Ziyou Chen,Yalin Wang,Fentian Chen,Xue Liu,Hai Yu,Quan Yuan,Ningshao Xia,Yuanzhi Chen,Wenxin Luo

DOI: https://doi.org/10.1093/abt/tbae016

2024-07-03

Abstract:Hepatitis B virus (HBV) infection is a significant global health concern due to elevated immunosuppressive viral antigen levels, the host immune system's inability to manage HBV, and the liver's immunosuppressive conditions. While immunotherapies utilizing broadly reactive HBV neutralizing antibodies present potential due to their antiviral capabilities and Fc-dependent vaccinal effects, they necessitate prolonged and frequent dosing to achieve optimal therapeutic outcomes. Toll-like receptor 7/8 (TLR7/8) agonists have been demonstrated promise for the cure of chronic hepatitis B, but their systemic use often leads to intense side effects. In this study, we introduced immune-stimulating antibody conjugates which consist of TLR7/8 agonists 1-[[4-(aminomethyl)phenyl]methyl]-2-butyl-imidazo[4,5-c]quinolin-4-amine (IMDQ) linked to an anti-hepatitis B surface antigen (HBsAg) antibody 129G1, and designated as 129G1-IMDQ. Our preliminary study highlights that 129G1-IMDQ can prompt robust and sustained anti-HBsAg specific reactions with short-term administration. This underscores the conjugate's potential as an effective strategy for HBsAg clearance and seroconversion, offering a fresh perspective for a practical therapeutic approach in the functional cure of CHB. Highlights: HBV-neutralizing antibody 129G1 was linked with a TLR7/8 agonist small molecule compound IMDQ.Treatment with 129G1-IMDQ has shown significant promise in lowering HBsAg levels in AAV/HBV mice.129G1-IMDQ were eliciting a strong and lasting anti-HBsAg immune response after short-term treatment in AAV/HBV mice.
Production of anti-HBx/CD3 BSAB secreting hybrid-hybridomas and application of the BSAB retargeting effector cells for lysis of human HCC xenografts in nude mice

Yong Liao,Zhaoyou Tang,Kangda Liu,Shenglong Ye,Jun Li,Zheng Huang,Dabin Wang,David M. Segal

1996-01-01

Abstract:Evidence indicated that the x gene of human HBV can cause cancer in transgenic mice; moreover, HBxAg was so far the most frequent and strong antigen among those HBV markers expressed in hepatocellular carcinoma (HCC) tissues. Aimed to enhance killing of HCC by effector cells, we established an anti-HBx/anti-CD3 hybrid-hybridoma by fusion of anti-HBx hybridoma cells with FITC-labelled anti-CD3 HAT sensitive cells, and followed by FACStar sterile cell sorting, HAT selection and eventually verified by ELISA and double binding assay. Application of this bispecific monoclonal antibody (BsAb) is in vitro effector: target cell conjugate assay by using two color cytometric analysis, we found that anti-HBx/anti-CD3 BsAb significantly enhanced the effector : target cell conjugate formation. In in vivo study, BsAb retargetting effector cells were more effective than that of effector cells alone in shrinkage of HCC xenografts in nude mice, not only in freshly inoculated tumors but also in established growing tumors (p < 0.01, p < 0.01). Besides, the apoptotic cells detected by in situ end-labelling technique were remarkable in tissues treated by BsAb plus effector cells. Pronounced infiltration of lymphocytes in the peripheral of tumor nodules can also be seen in the tissues treated by BsAb plus effector cells, but not in the controls. The results indicate that shrinkage of tumors in nude mice with therapy of BsAb retargetting effector cells was partly by initiation of apoptotic cell death in HCC cells.
IL-21-based therapies induce clearance of hepatitis B virus persistence in mouse models.

Zhongliang Shen,Jing Liu,Jingwen Wu,Yuanfei Zhu,Gaiyun Li,Jun Wang,Mengjun Luo,Qiang Deng,Jiming Zhang,Youhua Xie

DOI: https://doi.org/10.7150/thno.35331

IF: 11.6

2019-01-01

Theranostics

Abstract:Chronic hepatitis B virus (HBV) infection causes hepatitis, liver cirrhosis and hepatocellular carcinoma. Covalently closed circular DNA (cccDNA) is the sole viral transcription template and not affected by current treatment options, constituting a key determinant of HBV persistence. Novel therapeutics with demonstrable effectiveness against cccDNA are required. Methods: Previously, we established an HBV persistence mouse model using replicon plasmid derived from a clinical isolate (termed BPS) and identified IL-21 as a potent clearance-inducer. We also described another persistence mouse model based on cccDNA mimics produced in vivo termed recombinant cccDNA (rcccDNA). In this work, effectiveness of IL-21-based gene and cellular therapies was tested using these models. Results: In both models of HBV persistence, single injections with adeno-associated virus (AAV) expressing murine IL-21 highly efficiently induced clearance of both HBV markers from serum, and more importantly, BPS DNA and rcccDNA from mouse liver. Mechanistically, IL-21-induced clearance was associated with activation and liver infiltration of CD8(+) T cells, and CD8 antibody injections negatively affected AAV-IL-21 effectiveness. More notably, adoptive transfer of CD8 (+) T cells from AAV-IL-21-cured mice engendered clearance in acceptor HBV persistence mice. Furthermore, cured mice were protected against re-challenge with long-lived memory. Most significantly, infusion of splenocytes from treatment-naive mice stimulated ex vivo with IL-21 protein and HBV antigen could also induce clearance in treatment-naive mice. Conclusion: These data demonstrate IL-21-based gene and cellular therapies as valid candidates for treating chronic HBV infections, with potential in removing cccDNA-harboring hepatocytes via activated CD8(+) T cells accompanied by long-term protective memory.
Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen

Tian-Ying Zhang,Quan Yuan,Jing-Hua Zhao,Ya-Li Zhang,Lun-Zhi Yuan,Ying Lan,Yu-Chieh Lo,Cheng-Pu Sun,Chang-Ru Wu,Jun-Fang Zhang,Ying Zhang,Jia-Li Cao,Xue-Ran Guo,Xuan Liu,Xiao-Bing Mo,Wen-Xin Luo,Tong Cheng,Yi-Xin Chen,Mi-Hua Tao,James WK Shih,Qin-Jian Zhao,Jun Zhang,Pei-Jer Chen,Y Adam Yuan,Ning-Shao Xia

DOI: https://doi.org/10.1136/gutjnl-2014-308964

IF: 24.5

2015-09-30

Gut

Abstract:OBJECTIVE: This study aimed to investigate the therapeutic potential of monoclonal antibody (mAb) against HBV as a novel treatment approach to chronic hepatitis B (CHB) in mouse models.METHODS: Therapeutic effects of mAbs against various epitopes on viral surface protein were evaluated in mice mimicking persistent HBV infection. The immunological mechanisms of mAb-mediated viral clearance were systematically investigated.RESULTS: Among 11 tested mAbs, a novel mAb E6F6 exhibited the most striking therapeutic effects in several HBV-persistent mice. Single-dose administration of E6F6 could profoundly suppress the levels of hepatitis B surface antigen (HBsAg) and HBV DNA for several weeks in HBV-transgenic mice. E6F6 regimen efficiently prevented initial HBV infection, and reduced viral dissemination from infected hepatocytes in human-liver-chimeric mice. E6F6-based immunotherapy facilitated the restoration of anti-HBV T-cell response in hydrodynamic injection (HDI)-based HBV carrier mice. Immunological analyses suggested that the Fcγ receptor-dependent phagocytosis plays a predominant role in E6F6-mediated viral suppression. Molecular analyses suggested that E6F6 recognises an evolutionarily conserved epitope (GPCK(R)TCT) and only forms a smaller antibody-viral particle immune complex with limited interparticle crosslinking when it binds to viral particles. This unique binding characteristic of E6F6 to HBV was possibly associated with its effective in vivo opsonophagocytosis for viral clearance.CONCLUSIONS: These results provided new insight into understanding the therapeutic role and mechanism of antibody against persistent viral infection. The E6F6-like mAbs may provide a novel immunotherapeutic agent against human chronic HBV infection.

gastroenterology & hepatology
A new unconventional HLA-A2-restricted epitope from HBV core protein elicits antiviral cytotoxic T lymphocytes

Lu Sun,Yu Zhang,Bao Zhao,Mengmeng Deng,Jun Liu,Xin Li,Junwei Hou,Mingming Gui,Shuijun Zhang,Xiaodong Li,George F. Gao,Songdong Meng

DOI: https://doi.org/10.1007/s13238-014-0041-4

2014-03-22

Abstract:Cytotoxic T cells (CTLs) play a key role in the control of Hepatitis B virus (HBV) infection and viral clearance. However, most of identified CTL epitopes are derived from HBV of genotypes A and D, and few have been defined in virus of genotypes B and C which are more prevalent in Asia. As HBV core protein (HBc) is the most conservative and immunogenic component, in this study we used an overlapping 9-mer peptide pool covering HBc to screen and identify specific CTL epitopes. An unconventional HLA-A2-restricted epitope HBc141–149 was discovered and structurally characterized by crystallization analysis. The immunogenicity and anti-HBV activity were further determined in HBV and HLA-A2 transgenic mice. Finally, we show that mutations in HBc141–149 epitope are associated with viral parameters and disease progression in HBV infected patients. Our data therefore provide insights into the structure characteristics of this unconventional epitope binding to MHC-I molecules, as well as epitope specific CTL activity that orchestrate T cell response and immune evasion in HBV infected patients.

cell biology
Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus

S Zhen,L Hua,Y-H Liu,L-C Gao,J Fu,D-Y Wan,L-H Dong,H-F Song,X Gao

DOI: https://doi.org/10.1038/gt.2015.2

2015-02-05

Gene Therapy

Abstract:The current therapies to treat hepatitis B virus (HBV) infection are limited. Recently, clustered regularly interspaced short palindromic repeat (CRISPR) systems, originally identified in bacteria and archaea, have been found to consist of an RNA-based adaptive immune system that degrades complimentary sequences of invading plasmids and viruses. Here, we studied the effects of the CRISPR/CRISPR-associated Cas9 system that was targeted to the surface antigen (HBsAg)-encoding region of HBV, both in a cell culture system and in vivo. The HBsAg levels in the media of the cells and in the sera of mice were analyzed by a quantitative enzyme-linked immunosorbent assay. The HBV DNA levels were assessed by quantitative PCR and HBsAg expression in mouse livers was assessed by an immunohistochemical assay. The amount of HBsAg secreted in the cell culture and mouse serum was reduced by CRISPR/Cas9 treatment. Immunohistochemistry analyses showed almost no HBsAg-positive cells in the liver tissue of CRISPR/Cas9-S1+X3-treated mice. The CRISPR/Cas9 system efficiently produced mutations in HBV DNA. Thus, CRISPR/Cas9 inhibits HBV replication and expression in vitro and in vivo and may constitute a new therapeutic strategy for HBV infection.

genetics & heredity,biochemistry & molecular biology,medicine, research & experimental,biotechnology & applied microbiology
Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein

Laura Radić,Anna Offersgaard,Tereza Kadavà,Ian Zon,Joan Capella-Pujol,Fabian Mulder,Sylvie Koekkoek,Vera Spek,Ana Chumbe,Jens Bukh,Marit J van Gils,Rogier W Sanders,Victor C Yin,Albert J R Heck,Judith M Gottwein,Kwinten Sliepen,Janke Schinkel

DOI: https://doi.org/10.1101/2024.10.04.616615

2024-10-04

Abstract:Hepatitis C virus (HCV) currently causes about one million infections and 240,000 deaths worldwide each year. To reach the goal set by the World Health Organization (WHO) of global HCV elimination by 2030, it is critical to develop a prophylactic vaccine. Broadly neutralizing antibodies (bNAbs) target the E1E2 envelope glycoproteins on the viral surface, can neutralize a broad range of the highly diverse circulating HCV strains and are essential tools to inform vaccine design. However, bNAbs targeting a single E1E2 epitope might be limited in neutralization breadth, which can be enhanced by using combinations of bNAbs that target different envelope epitopes. We have generated 60 IgG-like bispecific antibodies (bsAbs) that can simultaneously target two distinct epitopes on E1E2. We combine non-overlapping E1E2 specificities into three types of bsAbs, each containing a different hinge length. The bsAbs show retained or increased potency and breadth against a diverse panel of HCV pseudoparticles (HCVpp) and HCV produced in cell culture (HCVcc) compared to monospecific and cocktail controls. Additionally, we demonstrate that changes in the hinge length of bsAbs can alter the binding stoichiometry to E1E2. These results provide insights into the binding modes and the role of avidity in bivalent targeting of diverse E1E2 epitopes, and suggest structural differences between HCVpp and HCVcc. This study illustrates how potential cooperative effects of HCV bNAbs can be utilized by strategically designing bispecific constructs. These new HCV bsAbs can guide vaccine development and unlock novel therapeutic and prophylactic strategies against HCV and other (flavi)viruses.

Microbiology
Activating adaptive immunity by bispecific, T-cell engager antibodies bridging infected and immune-effector cells is a promising novel therapy for chronic hepatitis B

Zhe Xie,Ulrike Protzer

DOI: https://doi.org/10.1016/j.antiviral.2024.105972

Abstract:Bispecific antibodies (bsAbs) are engineered immunoglobulins that combine two different antigen-binding sites in one molecule. BsAbs can be divided into two molecular formats: IgG-like and non-IgG-like antibodies. Structural elements of each format have implications for engaging the immune system. T cell engager antibodies (TCEs) are bsAbs designed to engage T cells with target cells. TCEs can be applied not only in cancer but also in infectious disease therapy to activate T-cell responses. In this review, we focus on current literature on the design and use of bsAbs as an innovative strategy to enhance adaptive antiviral immune responses. We summarized the novel T cell-related immunotherapies with a focus on TCEs, that are developed for the treatment of chronic hepatitis B. Chronic infection with the hepatitis B virus (HBV) had a death toll of 1.1 million humans in 2022, mainly due to liver cirrhosis and hepatocellular carcinoma developing in the more than 250 million humans chronically infected. A curative treatment approach for chronic hepatitis B is lacking. Combining antiviral therapy with immune therapies activating T-cell responses is regarded as the most promising therapeutic approach to curing HBV and preventing the sequelae of chronic infection. Attracting functionally intact T cells that are not HBV-specific and, therefore, have not yet been exposed to regulatory mechanisms and activating those at the target site in the liver is a very interesting therapeutic approach that could be achieved by TCEs. Thus, TCEs redirecting T cells toward HBV-positive cells represent a promising strategy for treating chronic hepatitis B and HBV-associated hepatocellular carcinoma.
A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice

Tian-Ying Zhang,Xue-Ran Guo,Yang-Tao Wu,Xiao-Zhen Kang,Qing-Bing Zheng,Ruo-Yao Qi,Bin-Bing Chen,Ying Lan,Min Wei,Shao-Juan Wang,Hua-Long Xiong,Jia-Li Cao,Bao-Hui Zhang,Xiao-Yang Qiao,Xiao-Fen Huang,Ying-Bin Wang,Mu-Jin Fang,Ya-Li Zhang,Tong Cheng,Yi-Xin Chen,Qin-Jian Zhao,Shao-Wei Li,Sheng-Xiang Ge,Pei-Jer Chen,Jun Zhang,Quan Yuan,Ning-shao Xia

DOI: https://doi.org/10.1136/gutjnl-2018-317725

IF: 24.5

2020-01-01

Gut

Abstract:Objective This study aimed to develop a novel therapeutic vaccine based on a unique B cell epitope and investigate its therapeutic potential against chronic hepatitis B (CHB) in animal models. Methods A series of peptides and carrier proteins were evaluated in HBV-tolerant mice to obtain an optimised therapeutic molecule. The immunogenicity, therapeutic efficacy and mechanism of the candidate were investigated systematically. Results Among the HBsAg-aa119-125-containing peptides evaluated in this study, HBsAg-aa113-135 (SEQ13) exhibited the most striking therapeutic effects. A novel immunoenhanced virus-like particle carrier (CR-T3) derived from the roundleaf bat HBV core antigen (RBHBcAg) was created and used to display SEQ13, forming candidate molecule CR-T3-SEQ13. Multiple copies of SEQ13 displayed on the surface of this particulate antigen promote the induction of a potent anti-HBs antibody response in mice, rabbits and cynomolgus monkeys. Sera and purified polyclonal IgG from the immunised animals neutralised HBV infection in vitro and mediated efficient HBV/hepatitis B virus surface antigen (HBsAg) clearance in the mice. CR-T3-SEQ13-based vaccination induced long-term suppression of HBsAg and HBV DNA in HBV transgenic mice and eradicated the virus completely in hydrodynamic-based HBV carrier mice. The suppressive effects on HBsAg were strongly correlated with the anti-HBs level after vaccination, suggesting that the main mechanism of CR-T3-SEQ13 vaccination therapy was the induction of a SEQ13-specific antibody response that mediated HBV/HBsAg clearance. Conclusions The novel particulate protein CR-T3-SEQ13 suppressed HBsAg effectively through induction of a humoural immune response in HBV-tolerant mice. This B cell epitope-based therapeutic vaccine may provide a novel immunotherapeutic agent against chronic HBV infection in humans.
Hepatitis B virus‐specific human stem cell memory T cells differentiate into cytotoxic T cells and eradicate HBV‐infected hepatocytes in mice

Hiromi Abe‐Chayama,Takakazu Kawase,Tatsuo Ichinohe,Yuji Ishida,Chise Tateno,Makoto Hijikata,Kazuaki Chayama

DOI: https://doi.org/10.1002/1873-3468.14842

2024-04-10

FEBS Letters

Abstract:Here, we detected stem cell memory T cells (TSCMs) in chronic hepatitis B virus (HBV)‐infected patients, using HBV core and polymerase peptide HLA tetramers. When these TSCMs were transferred into the human hepatocyte‐transplanted, HBV‐infected TK‐NOG mouse, they differentiated into cytotoxic T lymphocytes, produced interferon gamma and interleukin‐2, and developed histologically proven hepatitis. Furthermore, HBV DNA and human albumin in mouse serum declined and human hepatocytes were eliminated in the mouse model. Chronic infection with the hepatitis B virus (HBV) induces progressive hepatic impairment. Achieving complete eradication of the virus remains a formidable challenge. Cytotoxic T lymphocytes, specific to viral antigens, either exhibit a numerical deficiency or succumb to an exhausted state in individuals chronically afflicted with HBV. The comprehension of the genesis and dissemination of stem cell memory T cells (TSCMs) targeting HBV remains inadequately elucidated. We identified TSCMs in subjects with chronic HBV infection and scrutinized their efficacy in a murine model with human hepatocyte transplants, specifically the TK‐NOG mice. TSCMs were discerned in all subjects under examination. Introduction of TSCMs into the HBV mouse model precipitated a severe necro‐inflammatory response, resulting in the elimination of human hepatocytes. TSCMs may constitute a valuable tool in the pursuit of a remedial therapy for HBV infection.

cell biology,biochemistry & molecular biology,biophysics
CD8 cis-targeted IL-2 drives potent antiviral activity against hepatitis B virus

Francesco Andreata,Kelly D Moynihan,Valeria Fumagalli,Pietro Di Lucia,Danielle C Pappas,Keigo Kawashima,Irene Ni,Paul H Bessette,Chiara Perucchini,Elisa Bono,Leonardo Giustini,Henry C Nguyen,S Michael Chin,Yik Andy Yeung,Craig S Gibbs,Ivana Djuretic,Matteo Iannacone,Kelly D. Moynihan,Danielle C. Pappas,Paul H. Bessette,Henry C. Nguyen,S. Michael Chin,Craig S. Gibbs

DOI: https://doi.org/10.1126/scitranslmed.adi1572

IF: 17.1

2024-01-11

Science Translational Medicine

Abstract:CD8 + T cells are key antiviral effectors against hepatitis B virus (HBV), yet their number and function can be compromised in chronic infections. Preclinical HBV models displaying CD8 + T cell dysfunction showed that interleukin-2 (IL-2)–based treatment, unlike programmed cell death ligand 1 (PD-L1) checkpoint blockade, could reverse this defect, suggesting its therapeutic potential against HBV. However, IL-2's effectiveness is hindered by its pleiotropic nature, because its receptor is found on various immune cells, including regulatory T (T reg ) cells and natural killer (NK) cells, which can counteract antiviral responses or contribute to toxicity, respectively. To address this, we developed a cis-targeted CD8-IL2 fusion protein, aiming to selectively stimulate dysfunctional CD8 + T cells in chronic HBV. In a mouse model, CD8-IL2 boosted the number of HBV-reactive CD8 + T cells in the liver without substantially altering T reg or NK cell counts. These expanded CD8 + T cells exhibited increased interferon-γ and granzyme B production, demonstrating enhanced functionality. CD8-IL2 treatment resulted in substantial antiviral effects, evidenced by marked reductions in viremia and antigenemia and HBV core antigen–positive hepatocytes. In contrast, an untargeted CTRL-IL2 led to predominant NK cell expansion, minimal CD8 + T cell expansion, negligible changes in effector molecules, and minimal antiviral activity. Human CD8-IL2 trials in cynomolgus monkeys mirrored these results, achieving a roughly 20-fold increase in peripheral blood CD8 + T cells without affecting NK or T reg cell numbers. These data support the development of CD8-IL2 as a therapy for chronic HBV infection.

cell biology,medicine, research & experimental
Immunosuppressive Drug-Resistant Armored T-Cell Receptor T Cells for Immune Therapy of HCC in Liver Transplant Patients

Morteza Hafezi,Meiyin Lin,Adeline Chia,Alicia Chua,Zi Zong Ho,Royce Fam,Damien Tan,Joey Aw,Andrea Pavesi,Thinesh Lee Krishnamoorthy,Wan Cheng Chow,Wenjie Chen,Qi Zhang,Lu-En Wai,Sarene Koh,Anthony T Tan,Antonio Bertoletti

DOI: https://doi.org/10.1002/hep.31662

IF: 17.298

Hepatology

Abstract:Background and aims: HBV-specific T-cell receptor (HBV-TCR) engineered T cells have the potential for treating HCC relapses after liver transplantation, but their efficacy can be hampered by the concomitant immunosuppressive treatment required to prevent graft rejection. Our aim is to molecularly engineer TCR-T cells that could retain their polyfunctionality in such patients while minimizing the associated risk of organ rejection. Approach and results: We first analyzed how immunosuppressive drugs can interfere with the in vivo function of TCR-T cells in liver transplanted patients with HBV-HCC recurrence receiving HBV-TCR T cells and in vitro in the presence of clinically relevant concentrations of immunosuppressive tacrolimus (TAC) and mycophenolate mofetil (MMF). Immunosuppressive Drug Resistant Armored TCR-T cells of desired specificity (HBV or Epstein-Barr virus) were then engineered by concomitantly electroporating mRNA encoding specific TCRs and mutated variants of calcineurin B (CnB) and inosine-5'-monophosphate dehydrogenase (IMPDH), and their function was assessed through intracellular cytokine staining and cytotoxicity assays in the presence of TAC and MMF. Liver transplanted HBV-HCC patients receiving different immunosuppressant drugs exhibited varying levels of activated (CD39+ Ki67+ ) peripheral blood mononuclear cells after HBV-TCR T-cell infusions that positively correlate with clinical efficacy. In vitro experiments with TAC and MMF showed a potent inhibition of TCR-T cell polyfunctionality. This inhibition can be effectively negated by the transient overexpression of mutated variants of CnB and IMPDH. Importantly, the resistance only lasted for 3-5 days, after which sensitivity was restored. Conclusions: We engineered TCR-T cells of desired specificities that transiently escape the immunosuppressive effects of TAC and MMF. This finding has important clinical applications for the treatment of HBV-HCC relapses and other pathologies occurring in organ transplanted patients.
Combination therapy of therapeutic antibody and vaccine or entecavir in HBV carrier mice

Ruoyao Qi,Jiali Cao,Yangtao Wu,Xing Lei,Jinhang He,Liang Zhang,Rao Fu,Feng Chen,Yingbin Wang,Tianying Zhang,Ningshao Xia,Quan Yuan

DOI: https://doi.org/10.3389/fmicb.2023.1173061

IF: 5.2

2023-05-06

Frontiers in Microbiology

Abstract:Chronic infection with the hepatitis B virus (HBV) is a leading causes of liver cirrhosis and hepatocellular carcinoma. However, managing HBV treatments is challenging due to the lack of effective monotherapy. Here, we present two combination approaches, both of which aim to target and enhance the clearance of HBsAg and HBV-DNA. The first approach involves the use of antibodies to continuously suppress HBsAg, followed by the administration of a therapeutic vaccine in a sequential manner. This approach results in better therapeutic outcomes compared to the use of these treatments individually. The second approach involves combining antibodies with ETV, which effectively overcomes the limitations of ETV in suppressing HBsAg. Thus, the combination of therapeutic antibodies, therapeutic vaccines, and other existing drugs is a promising strategy for the development of novel strategies to treat hepatitis B.

microbiology
Hepatitis B virus as a gene delivery vector activating foreign antigenic T cell response that abrogates viral expression in mouse models.

Qiang Deng,Maryline Mancini-Bourgine,Xiaoming Zhang,Marie-Christine Cumont,Ren Zhu,Yu-Chun Lone,Marie-Louise Michel

DOI: https://doi.org/10.1002/hep.23150

2009-01-01

Abstract:UNLABELLED:Chronic hepatitis B virus (HBV) infection is characterized by functionally impaired T cell responses. To ensure active immunotherapy, the immune response must be switched from exhausted T cells to functional effectors that can attain the liver and cure the viral infection. We thus designed a recombinant HBV (rHBV) containing a modified viral core gene that specifically delivers a foreign antigenic polyepitope to the liver. This recombinant virus could only be self-maintained in hepatocytes already infected by HBV through capsid complementation. A strong foreign epitope-specific T cell response was first primed in the periphery by way of DNA immunization in human leukocyte antigen (HLA)-A2/DR1 transgenic mice. After the hydrodynamic (hyd.) injection of rHBV, expression of the foreign antigenic polyepitope in hepatocytes attracted/reactivated a vigorous T cell response in situ. Most liver-infiltrating CD8(+) T cells proved to be functional effectors. Following DNA priming and hyd. injection, the rHBV-based expression of hepatitis B surface antigen (HBsAg) in mouse liver was almost completely inhibited without causing major liver injury. Studies in HBsAg/HLA-A2/DR1 transgenic mice further validated our approach. CONCLUSION:For the first time, HBV was used as a gene delivery vector, which strongly triggered functional T cell response and subsequently controlled the viral expression in the liver of surrogate mouse models for HBV infection. It might represent an innovative and promising strategy of active immunotherapy during HBV persistent infection. This concept could even be more generally extended to other chronic viral diseases.
Clearing Persistent Extracellular Antigen of Hepatitis B Virus: an Immunomodulatory Strategy to Reverse Tolerance for an Effective Therapeutic Vaccination

Danming Zhu,Longchao Liu,Dan Yang,Sherry Fu,Yingjie Bian,Zhichen Sun,Junming He,Lishan Su,Liguo Zhang,Hua Peng,Yang-Xin Fu

DOI: https://doi.org/10.4049/jimmunol.1502061

2016-01-01

Abstract:Development of therapeutic vaccines/strategies to control chronic hepatitis B virus (HBV) infection has been challenging because of HBV-induced tolerance. In this study, we explored strategies for breaking tolerance and restoring the immune response to the HBV surface Ag in tolerant mice. We demonstrated that immune tolerance status is attributed to the level and duration of circulating HBsAg in HBV carrier models. Removal of circulating HBsAg by a monoclonal anti-HBsAg Ab in tolerant mice could gradually reduce tolerance and reestablish B cell and CD4+ T cell responses to subsequent Engerix-B vaccination, producing protective IgG. Furthermore, HBsAg-specific CD8+ T cells induced by the addition of a TLR agonist resulted in clearance of HBV in both serum and liver. Thus, generation of protective immunity can be achieved by clearing extracellular viral Ag with neutralizing Abs followed by vaccination.
An Efficient Antiviral Strategy for Targeting Hepatitis B Virus Genome Using Transcription Activator-Like Effector Nucleases

Jieliang Chen,Wen Zhang,Junyu Lin,Fan Wang,Min Wu,Cuncun Chen,Ye Zheng,Xiuhua Peng,Jianhua Li,Zhenghong Yuan

DOI: https://doi.org/10.1038/mt.2013.212

IF: 12.91

2014-01-01

Molecular Therapy

Abstract:The hepatitis B virus (HBV) is a DNA virus that can cause chronic hepatitis B (CHB) in humans. Current therapies for CHB infection are limited in efficacy and do not target the pre-existing viral genomic DNA, which are present in the nucleus as a covalently closed circular DNA (cccDNA) form. The transcription activator-like (TAL) effector nucleases (TALENs) are newly developed enzymes that can cleave sequence-specific DNA targets. Here, TALENs targeting the conserved regions of the viral genomic DNA among different HBV genotypes were constructed. The expression of TALENs in Huh7 cells transfected with monomeric linear full-length HBV DNA significantly reduced the viral production of HBeAg, HBsAg, HBcAg, and pgRNA, resulted in a decreased cccDNA level and misrepaired cccDNAs without apparent cytotoxic effects. The anti-HBV effect of TALENs was further demonstrated in a hydrodynamic injection-based mouse model. In addition, an enhanced antiviral effect with combinations of TALENs and interferon-α (IFN-α) treatment was observed and expression of TALENs restored HBV suppressed IFN-stimulated response element-directed transcription. Taken together, these data indicate that TALENs can specifically target and successfully inactivate the HBV genome and are potently synergistic with IFN-α, thus providing a potential therapeutic strategy for treating CHB infection.

Stability Analysis of Smith predictor Based Networked Control Systems with Time-varying delays

In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma

Targeted Delivery of Interferon-Α to Hepatitis B Virus-Infected Cells Using T-cell Receptor-Like Antibodies.

A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy

A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations

HBsAg and TLR7/8 dual-targeting antibody-drug conjugates induce sustained anti-HBV activity in AAV/HBV mice: a preliminary study

Production of anti-HBx/CD3 BSAB secreting hybrid-hybridomas and application of the BSAB retargeting effector cells for lysis of human HCC xenografts in nude mice

IL-21-based therapies induce clearance of hepatitis B virus persistence in mouse models.

Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen

A new unconventional HLA-A2-restricted epitope from HBV core protein elicits antiviral cytotoxic T lymphocytes

Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus

Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein

Activating adaptive immunity by bispecific, T-cell engager antibodies bridging infected and immune-effector cells is a promising novel therapy for chronic hepatitis B

A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice

Hepatitis B virus‐specific human stem cell memory T cells differentiate into cytotoxic T cells and eradicate HBV‐infected hepatocytes in mice

CD8 cis-targeted IL-2 drives potent antiviral activity against hepatitis B virus

Immunosuppressive Drug-Resistant Armored T-Cell Receptor T Cells for Immune Therapy of HCC in Liver Transplant Patients

Combination therapy of therapeutic antibody and vaccine or entecavir in HBV carrier mice

Hepatitis B virus as a gene delivery vector activating foreign antigenic T cell response that abrogates viral expression in mouse models.

Clearing Persistent Extracellular Antigen of Hepatitis B Virus: an Immunomodulatory Strategy to Reverse Tolerance for an Effective Therapeutic Vaccination

An Efficient Antiviral Strategy for Targeting Hepatitis B Virus Genome Using Transcription Activator-Like Effector Nucleases